Abstract: Objective To explore the correlation between the expression of F-box only protein 22 (FBXO22) and human papilloma virus (HPV) genotypes and pathological findings in patients with cervical cancer. 
Methods A total of 108 patients with cervical cancer were selected for HPV test, and HPV genotyping was performed. The expression of FBXO22 protein was detected by immunohistochemistry, and correlation among indicators was evaluated by Spearman rank correlation analysis. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic performance. 
Results The positive expression rate of FBXO22 was 91.67% in high-risk HPV patients and 69.44% in low-risk HPV patients. The positive expression rate of FBXO22 in the high-risk HPV group was higher than that in the low-risk HPV group (P＜0.05). With an increase in the number of stages Ⅰ to Ⅳ of squamous cell carcinoma, the positive expression rate of FBXO22 also increased (P＜0.05). With the increase in the degree of differentiation, the positive expression rate of FBXO22 decreased (P＜0.05). There was a positive correlation between high-risk and low-risk HPV infection and FBXO22 protein levels (r=0.859, 0.704, P=0.005, 0.009). The degree of differentiation and clinical stage were positively correlated with FBXO22 protein levels (r=0.884, 0.873, P=0.002, 0.003). The ROC curve analysis results showed that the specificity and the area under the ROC curve (AUC) of FBXO22 protein combined with hrHPV DNA detection were 89.23% and 0.823%, respectively, which were significantly higher than those detected by each indicator alone (P＜0.001). 
Conclusion The expression of FBXO22 in cervical cancer patients is closely related to high-risk HPV infection, and also reflects the differentiation degree and clinical stage of cervical cancer patients. The combined detection of FBXO22 and high-risk HPV is of great significance for the early prevention and treatment of cervical cancer.

Key words: uterine cervical neoplasms, FBXO22, papillomaviridae